According to 2021 data from the American Diabetes Association, 2 million Americans have type 1 diabetes—304,000 of which are ...

"The risk of diabetic ketoacidosis linked to continuous subcutaneous insulin infusion in type 1 diabetes has significantly ...

Control-IQ+ automated insulin delivery technology from Tandem Diabetes Care cleared by FDA for people with type 2 diabetes.

Insulin solutions must be placed in an infusion pump and piggybacked into the lower distal port of a maintenance i.v. line with a rate of at least 20 mL/hr. (Use 0.9% sodium chloride injection if ...

Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults ...

ViCentra announced today that it appointed Tom Arnold as its new CEO to accelerate growth with the Kaleido automated insulin ...

Tandem Diabetes Care (Nasdaq:TNDM) shares took a hit after hours today on fourth-quarter results that topped the consensus ...

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes.

Welcome to the era of algorithm-driven diabetes management, where closed-loop glucose monitoring systems keep you from ...

Tandem Diabetes Care, Inc. reported strong Q4 2024 earnings, but shares declined 30%. Click for my TNDM stock update in light ...

Embecta's compelling ~44% free cash flow yield offers a strong risk-reward despite headwinds from new insulin technologies ...

BofA initiated coverage of Beta Bionics (BBNX) with a Buy rating and $25 price target Beta’s iLet insulin pump simplifies insulin-dosing for ...